Track topics on Twitter Track topics that are important to you
Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death All mentions of NLY01 have been corrected. The corrected release reads: NEURALY AN...
Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents fo...
D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical re...
NLY01 is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood-brain barrier (BBB) in animal models and its receptor (GLP-1R...
We have published hundreds of Neuraly news stories on BioPortfolio along with dozens of Neuraly Clinical Trials and PubMed Articles about Neuraly for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neuraly Companies in our database. You can also find out about relevant Neuraly Drugs and Medications on this site too.